Otsuka Holdings Co., Ltd. (OTSKY) Q2 FY2024 Earnings Call Transcript

Otsuka Holdings (OTCPK:OTSKY) reported strong Q2 FY2024 financial results, with revenue increasing 17.0% to JPY 1,108.9 billion and business profit surging 37.8% to JPY 213.6 billion, primarily driven by robust sales in its pharmaceutical and nutraceutical businesses. Despite an impairment loss on AVP-786 affecting operating profit, net profit still rose 5.1% due to finance income, and operating cash flow before R&D investment also increased by approximately JPY 20 billion. These results notably exceeded the company's revised plan, underscoring strong operational performance and the effectiveness of its strategic growth drivers like Rexulti and LONSURF.

Analysis

Otsuka Holdings reported a robust second quarter for fiscal year 2024, demonstrating significant operational strength. Revenue surged 17.0% year-over-year to JPY 1,108.9 billion, while business profit grew an even more impressive 37.8% to JPY 213.6 billion, fueled by strong performance in its core pharmaceutical and nutraceutical segments. This top-line and profit momentum led the company to exceed its own revised plan announced in May, signaling strong execution. A notable headwind was an impairment loss on AVP-786, which suppressed operating profit; however, the impact was partially mitigated by finance income, allowing net profit to still record a 5.1% increase. Furthermore, the company's financial health is underscored by a JPY 20 billion year-over-year increase in operating cash flow before R&D investment. Strategically, the firm has clarified its growth drivers under a new midterm plan, positioning products like Rexulti and LONSURF as 'Core 2' growth engines, indicating a clear focus for future performance.

Key Decisions for Investors

• Given the significant outperformance against revised guidance, with 17% revenue and 37.8% business profit growth, the current results support a bullish view on the company's core operational momentum.
• Investors should scrutinize the one-off nature of the AVP-786 impairment loss, as any further write-downs could continue to pressure operating profit despite the strong underlying business performance.
• The substantial increase in operating cash flow reinforces the company's capacity to fund its strategic pipeline, and investors should monitor the sales trajectory of the designated 'Core 2' growth drivers to validate the long-term outlook.